Antibody-mediated Rejection Market Trends
Antibody-mediated rejection (AMR)—or humoral rejection—after renal transplantation is a devastating event that inevitably led to allograft loss. AMR poses a significant and continued challenge for long term graft survival in kidney transplantation. In the continuum of allograft rejection, the development of antibodies plays a critical role, and antibodies are considered a major cause of allograft failure.
According to the study conducted by Puttarajappa et al. (2012), acute AMR occurs in about 5–7% of all kidney transplants and is responsible for 20–48% of acute rejection episodes among pre-sensitized positive crossmatch patients.
DelveInsight's "Antibody-mediated Rejection Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the Antibody-mediated Rejection Market, historical and forecasted epidemiology, the pipeline insight as well as the Antibody-mediated Rejection market size and shares analysis in the seven major markets (7MM) (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Antibody-mediated Rejection Market Analysis
The Antibody-mediated Rejection market analysis section of the report helps to build a detailed comprehension of the historic, current and forecasted Antibody-mediated Rejection market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand for better technology.
The report gives a thorough detail of Antibody-mediated Rejection market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Antibody-mediated Rejection Epidemiology Forecast
The Antibody-mediated Rejection epidemiology section covers insights about historical and current Antibody-mediated Rejection patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Antibody-mediated Rejection Pipeline Analysis and Key Companies
The Antibody-mediated Rejection Pipeline and Drugs Uptake section focus on the rate of uptake of the potential drugs recently launched in the Antibody-mediated Rejection market or expected to get launched in the market during the study period. The analysis covers the Antibody-mediated Rejection market uptake by drugs; patient uptake by therapies; and sales of each drug.
The primary aim of therapeutic approaches to Antibody-mediated rejection is to remove circulating donor-specific anti-HLA antibodies and to block their effects, reduce their production, or both.
Some of the key companies in the Antibody-Mediated Rejection market include:
Bristol-Myers Squibb
CSL Behring
Hansa Biopharma AB
And others.
Antibody-Mediated Rejection Therapies Covered: Nulojix (belatacept), Clazakizumab, Imlifidase, and many others.
Source: Antibody-mediated Rejection Market Trends